inclusion criteria: 1. adult 18 years of age or older. 2. symptomatic and within 7 days of symptom onset. 3. high risk for severe disease (as defined by one or more of the following): 1. age \>50 2. diabetes mellitus requiring therapy 3. hypertension on medication 4. bmi \>30 kg/m2 5. cardiovascular disease 6. asthma requiring chronic controller medication 7. symptomatic respiratory disease 8. immunosuppressed patients (to maximum of 10mg prednisone daily +/- other immunosuppressive agents) 9. documented fever (\>38c) 10. one or more of the following symptoms: cough, shortness of breath (sob), pleuritic chest pain and/or myalgias (to a maximum of 25% of enrollment) 4. discharged to home isolation. 5. willing and able to provide informed consent (including by substitute decision maker). 6. willing and able to follow-up by phone or videoconference. 7. female patients of childbearing potential and male patients with partners of childbearing potential must agree to use adequate methods of contraception during the study and through 90 days after the last dose of study medication. female patients of childbearing potential are all those except patients who are surgically sterile, who have medically documented ovarian failure, or who are at least 1 year postmenopausal.

inclusion criteria: 1. adult 18 years of age or older. 2. symptomatic and within 7 days of symptom onset. 3. high risk for severe disease (as defined by one or more of the following): 1. age \>50 2. diabetes mellitus requiring therapy 3. hypertension on medication 4. bmi \>30 kg/m2 5. cardiovascular disease 6. asthma requiring chronic controller medication 7. symptomatic respiratory disease 8. immunosuppressed patients (to maximum of 10mg prednisone daily +/- other immunosuppressive agents) 9. documented fever (\>38c) 10. one or more of the following symptoms: cough, shortness of breath (sob), pleuritic chest pain and/or myalgias (to a maximum of 25% of enrollment) 4. discharged to home isolation. 5. willing and able to provide informed consent (including by substitute decision maker). 6. willing and able to follow-up by phone or videoconference. 7. female patients of childbearing potential and male patients with partners of childbearing potential must agree to use adequate methods of contraception during the study and through 90 days after the last dose of study medication. female patients of childbearing potential are all those except patients who are surgically sterile, who have medically documented ovarian failure, or who are at least 1 year postmenopausal.

inclusion criteria: adult 18 years of age or older. symptomatic and within 7 days of symptom onset. high risk for severe disease (as defined by one or more of the following): age >50 diabetes mellitus requiring therapy hypertension on medication bmi >30 kg/m2 cardiovascular disease asthma requiring chronic controller medication symptomatic respiratory disease immunosuppressed patients (to maximum of 10mg prednisone daily +/- other immunosuppressive agents) documented fever (>38c) one or more of the following symptoms: cough, shortness of breath (sob), pleuritic chest pain and/or myalgias (to a maximum of 25% of enrollment) discharged to home isolation. willing and able to provide informed consent (including by substitute decision maker). willing and able to follow-up by phone or videoconference. female patients of childbearing potential and male patients with partners of childbearing potential must agree to use adequate methods of contraception during the study and through 90 days after the last dose of study medication. female patients of childbearing potential are all those except patients who are surgically sterile, who have medically documented ovarian failure, or who are at least 1 year postmenopausal.

inclusion criteria: adult 18 years of age or older. symptomatic and within 7 days of symptom onset. high risk for severe disease (as defined by one or more of the following): age >50 diabetes mellitus requiring therapy hypertension on medication bmi >30 kg/m2 cardiovascular disease asthma requiring chronic controller medication symptomatic respiratory disease immunosuppressed patients (to maximum of 10mg prednisone daily +/- other immunosuppressive agents) documented fever (>38c) one or more of the following symptoms: cough, shortness of breath (sob), pleuritic chest pain and/or myalgias (to a maximum of 25% of enrollment) discharged to home isolation. willing and able to provide informed consent (including by substitute decision maker). willing and able to follow-up by phone or videoconference. female patients of childbearing potential and male patients with partners of childbearing potential must agree to use adequate methods of contraception during the study and through 90 days after the last dose of study medication. female patients of childbearing potential are all those except patients who are surgically sterile, who have medically documented ovarian failure, or who are at least 1 year postmenopausal.

inclusion criteria: 1. adult 18 years of age or older. 2. symptomatic and within 7 days of symptom onset. 3. high risk for severe disease (as defined by one or more of the following): 1. age >50 2. diabetes mellitus requiring therapy 3. hypertension on medication 4. bmi >30 kg/m2 5. cardiovascular disease 6. asthma requiring chronic controller medication 7. symptomatic respiratory disease 8. immunosuppressed patients (to maximum of 10mg prednisone daily +/- other immunosuppressive agents) 9. documented fever (>38c) 10. one or more of the following symptoms: cough, shortness of breath (sob), pleuritic chest pain and/or myalgias (to a maximum of 25% of enrollment) 4. discharged to home isolation. 5. willing and able to provide informed consent (including by substitute decision maker). 6. willing and able to follow-up by phone or videoconference. 7. female patients of childbearing potential and male patients with partners of childbearing potential must agree to use adequate methods of contraception during the study and through 90 days after the last dose of study medication. female patients of childbearing potential are all those except patients who are surgically sterile, who have medically documented ovarian failure, or who are at least 1 year postmenopausal.

inclusion criteria: 1. adult 18 years of age or older. 2. symptomatic and within 7 days of symptom onset. 3. high risk for severe disease (as defined by one or more of the following): 1. age >50 2. diabetes mellitus requiring therapy 3. hypertension on medication 4. bmi >30 kg/m2 5. cardiovascular disease 6. asthma requiring chronic controller medication 7. symptomatic respiratory disease 8. immunosuppressed patients (to maximum of 10mg prednisone daily +/- other immunosuppressive agents) 9. documented fever (>38c) 10. one or more of the following symptoms: cough, shortness of breath (sob), pleuritic chest pain and/or myalgias (to a maximum of 25% of enrollment) 4. discharged to home isolation. 5. willing and able to provide informed consent (including by substitute decision maker). 6. willing and able to follow-up by phone or videoconference. 7. female patients of childbearing potential and male patients with partners of childbearing potential must agree to use adequate methods of contraception during the study and through 90 days after the last dose of study medication. female patients of childbearing potential are all those except patients who are surgically sterile, who have medically documented ovarian failure, or who are at least 1 year postmenopausal.